| Released | Contributor | Author | Title | Pages | Price |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 26-Nov-2009 | New Constructs, LLC |
N/A
| MNKD: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | MANNKIND CORPORATION (MNKD=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of MANNKIND CORP including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for MNKD | 13 |
$25 |
| 21-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| MannKind Corp | 5 |
$25 |
| 20-Nov-2009 | Pechala's Reports | Frantisek Pechala | MANNKIND CP (MNKD=US) 12-months forecast | 1 |
$15 |
| 20-Nov-2009 | Pechala's Reports | Lubomir Pechala | MANNKIND CP (MNKD=US) 2-weeks forecast | 1 |
$10 |
| 19-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: CADX , MNKD , MDVN , NVD -- DRUGS | 3 |
$4 |
1.48% Nasdaq 
Research Reports
